



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Adress: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NO.                   | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |  |
|-----------------------------------|-------------|----------------------|---------------------|------------------|--|
| 10/803,793                        | 03/18/2004  | Erik Buntinx         | 29248/21            | 5618             |  |
| 1912                              | 7590        | 06/08/2010           |                     |                  |  |
| AMSTER, ROTHSTEIN & EBENSTEIN LLP |             |                      |                     | EXAMINER         |  |
| 90 PARK AVENUE                    |             | PACKARD, BENJAMIN J  |                     |                  |  |
| NEW YORK, NY 10016                |             | ART UNIT             | PAPER NUMBER        |                  |  |
|                                   |             | 1612                 |                     |                  |  |
|                                   |             | MAIL DATE            | DELIVERY MODE       |                  |  |
|                                   |             | 06/08/2010           | PAPER               |                  |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

|                              |                                      |                                      |
|------------------------------|--------------------------------------|--------------------------------------|
| <b>Office Action Summary</b> | <b>Application No.</b><br>10/803,793 | <b>Applicant(s)</b><br>BUNTINX, ERIK |
|                              | <b>Examiner</b><br>Benjamin Packard  | <b>Art Unit</b><br>1612              |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 11 February 2010.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 49,50,55,72,92 and 93 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) 50,55,92 and 93 is/are allowed.

6) Claim(s) 49 and 72 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statements (PTO/SB/06)  
 Paper No(s)/Mail Date 4pgs 02/11/2010.

4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date. \_\_\_\_\_.

5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

#### **DETAILED ACTION**

Applicants' arguments, filed 2/11/10, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

#### ***Claim Rejections - 35 USC § 103***

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

**Claim 49** stands rejected under 35 U.S.C. 103(a) as being unpatentable over Müller (Expert Opinion on Pharmacotherapy, 2002, Vol. 3, No 4, pp. 381-388) in view of PERMAX® prescribing information ([http://www.fda.gov/medwatch/safety/2003/permax\\_PI.pdf](http://www.fda.gov/medwatch/safety/2003/permax_PI.pdf), revised October 2, 2003, pp. 1-2) and Kuhajda et al (US 5,759,837).

Applicants assert amending the recitation of "a therapeutically effective amount" of the active provides a sufficient nexus between the results and the amount of active where the claim also recites "for use for treating Parkinson Disease".

Examiner disagrees. First, Examiner notes "for use for treating Parkinson Disease" is simply one intended use, and therefore not limiting on the use of the phrase "a therapeutically effective amount".

Second, even if a nexus were found between the two phrases, the amount of active may vary, such as if there is an additional active agent present or the a reduced

dosage amount. Either way, where only a minimal amount of dopamine receptor agonist is administered, it is unclear if the resulting benefit would be unexpected, given the side effects would also be minimized by the reduced dosage.

**Claim 72** stands rejected under 35 U.S.C. 103(a) as being unpatentable over Müller (Expert Opinion on Pharmacotherapy, 2002, Vol. 3, No 4, pp. 381-388) in view of Nystrom et al. (US 5,6345,213).

Because Applicants did not specifically address this rejection, this rejection is maintained for the reasons stated above.

***Allowable Subject Matter***

**Claims 50, 55, 92, and 93** remain allowable for the reasons of record.

***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin Packard whose telephone number is 571-270-3440. The examiner can normally be reached on M-R 8-6 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Benjamin Packard/  
Examiner, Art Unit 1612

/Frederick Krass/  
Supervisory Patent Examiner, Art Unit 1612